Marketing Authorization Application for Lipsovir® now validated by American and European regulatory authorities

Marketing Authorization Application for Lipsovir® now validated by American and
European regulatory authorities 

Medivir announced today that the American (FDA) and European regulatory
authorities have validated the NDA and Marketing Authorization Application for
Lipsovir®. 

The authorities will start the review process to evaluate the data submitted by
Medivir. The outcome of this review is expected to be received in the late part
of third quarter 2009.

Lipsovir® is a topical product for prevention and treatment of cold sores.
Lipsovir® is a patented combination of hydrocortisone (an anti-inflammatory
agent) and acyclovir (an antiviral agent) in a proprietary cream base developed
by Medivir.



For additional information please contact
Rein Piir, CFO & VP, Investor Relations at Medivir, +46 8 5468 3123 or +46 708
537292

For more information on Medivir, please see the company website www.medivir.se